OpenEvidence Inc.

OpenEvidence Inc. is an American artificial intelligence company that develops a medical search engine for clinical decision support. Verified physicians use the platform at no cost to query peer-reviewed medical literature and receive synthesized, cited answers to clinical questions. The company was founded in 2022 by Daniel Nadler, who previously founded the financial analytics firm Kensho Technologies (acquired by S&P Global in 2018), and Zachary Ziegler, a Harvard machine learning researcher who serves as chief technology officer. OpenEvidence is headquartered in Miami, Florida.

The core product is free to verified U.S. physicians, with revenue generated through advertising. Its DeepConsult feature, launched in July 2025, runs deeper multi-step research across the medical literature. OpenEvidence holds content partnerships with the New England Journal of Medicine and JAMA Network publications and works with organizations including the American Medical Association, the National Comprehensive Cancer Network, and the American Academy of Family Physicians. The company came up through the Mayo Clinic Platform Accelerate program, and its AI engine also powers Elsevier's ClinicalKey AI. As of December 2025 the platform counted roughly 760,000 registered U.S. physicians and about 18 million clinical consultations per month.

OpenEvidence has raised approximately $700 million. Sequoia Capital led a $75 million Series A in February 2025 at a $1 billion valuation, followed by a $210 million round led by GV and Kleiner Perkins in July 2025 at $3.5 billion, a $200 million Series C in October 2025 at $6 billion, and a $250 million Series D led by Thrive Capital and DST Global in January 2026 that valued the company at $12 billion. Other backers include Nvidia, Blackstone, Craft Ventures, and Mayo Clinic. The company ranked No. 32 on the 2026 CNBC Disruptor 50 list and operates with a small staff, with third-party estimates ranging from roughly 60 to 120 employees.